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Abstract 
Background: Semi‑immunity against the malaria parasite is defined by a protection against clinical episodes of 
malaria and is partially mediated by a repertoire of inhibitory antibodies directed against the blood stage of Plasmo-
dium falciparum, in particular against surface proteins of merozoites, the invasive form of the parasite. Such antibodies 
may be used for preventive or therapeutic treatment of P. falciparum malaria. Here, the isolation and characterization 
of novel human monoclonal antibodies (humAbs) for such applications is described.
Methods: B lymphocytes had been selected by flow cytometry for specificity against merozoite surface proteins, 
including the merozoite surface protein 10 (MSP10). After Epstein‑Barr virus (EBV) transformation and identification of 
promising resulting lymphoblastoid cell lines (LCLs), human immunoglobulin heavy and light chain variable regions 
(Vh or Vl regions) were secured, cloned into plant expression vectors and transiently produced in Nicotiana benthami-
ana in the context of human full‑size IgG1:κ. The specificity and the affinity of the generated antibodies were assessed 
by ELISA, dotblot and surface plasmon resonance (SPR) spectroscopy. The growth inhibitory activity was evaluated 
based on growth inhibition assays (GIAs) using the parasite strain 3D7A.
Results: Supernatants from two LCLs, 5E8 and 5F6, showed reactivity against the second (5E8) or first (5F6) epidermal 
growth factor (EGF)‑like domain of MSP10. The isolated V regions were recombinantly expressed in their natural pair‑
ing as well as in combination with each other. The resulting recombinant humAbs showed affinities of 9.27 × 10−7 M 
[humAb10.1 (H5F6:κ5E8)], 5.46 × 10−9 M [humAb10.2 (H5F6:κ5F6)] and 4.34 × 10−9 M [humAb10.3 (H5E8:κ5E8)]. In 
GIAs, these antibodies exhibited EC50 values of 4.1 mg/ml [95% confidence interval (CI) 2.6–6.6 mg/ml], 6.9 mg/ml  
(CI 5.5–8.6 mg/ml) and 9.5 mg/ml (CI 5.5–16.4 mg/ml), respectively.
Conclusion: This report describes a platform for the isolation of human antibodies from semi‑immune blood donors 
by EBV transformation and their subsequent characterization after transient expression in plants. To our knowledge, 
the presented antibodies are the first humAbs directed against P. falciparum MSP10 to be described. They recognize 
the EGF‑like folds of MSP10 and bind these with high affinity. Moreover, these antibodies inhibit P. falciparum 3D7A 
growth in vitro.
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Background
Malaria still claims over half a million victims each year 
and poses a significant burden to global health care and 
to the economy of endemic countries [1]. In humans, 
semi-immunity to clinical malaria develops slowly due to 
high allelic variations in many immuno-relevant plasmo-
dial antigens, is incomplete and wanes quickly without 
frequent reinfections [2–4]. Several lines of defense con-
tribute to the immune response against the erythrocytic 
stages of plasmodia, e.g. innate-like Vγ9:Vδ2 T cells [5] 
and anti-plasmodial antibodies. The repertoire and spec-
trum of antibodies which eventually can prevent clinical 
episodes of malaria gradually develops with cumulative 
exposure to infections [6–8]. Passive transfer of naturally 
acquired antibodies has been shown to reduce parasitae-
mia in infected individuals [9, 10]. Such anti-plasmodial 
antibodies may mediate protection by prevention of 
re-invasion of merozoites into new erythrocytes [11], 
by antibody-dependent cellular inhibition mediated by 
monocytes [3, 12] and by antibody-dependent respira-
tory burst mediated by neutrophil granulocytes [13].
Most of the antibodies used for studies in the malaria 
field originate from rodents or rabbits. Unquestionably, 
these antibodies are valuable tools. However, they do not 
reflect the human immunoglobulin repertoire of semi-
immune individuals. Malaria vaccine development is 
focusing on targets from the three major life cycle stages 
of the parasite in humans, the liver stage, the blood stage 
and the sexual stage. Sterile immunity, induced by experi-
mental malaria infection, is mainly conferred by immune 
responses against the pre-erythrocytic stages [14]. How-
ever, immune responses in natural infection in hyper- 
and holoendemic regions are primarily focused on the 
blood stage and the protection is incomplete [15]. Targets 
of this immune response mediating partial protection are 
mainly surface proteins of the merozoite stage. Mem-
bers of the merozoite surface protein (MSP) family, the 
reticulocyte homology (Rh) and the erythrocyte-binding 
like (EBL) proteins as well as the apical membrane anti-
gen 1 (AMA1) play a central role. All of these proteins 
are in the focus of vaccine candidate studies [16]. One of 
the most recently identified members of the MSP fam-
ily is MSP10. MSP10 was first described by Black et al., 
but until today there is little known about the function 
of this protein and whether it is essential [17]. Under 
the assumption that the genome of Plasmodium falcipa-
rum encodes more than one MSP that contains a dou-
ble epidermal growth factor (EGF)-like domain, Black 
et  al. sought to identify potential homologs of MSP1. It 
appears that MSP1 and MSP10 have several features in 
common; i.e. they share a double EGF-like domain and 
a glycosylphosphatidylinositol (GPI) anchor at their 
C-terminus and both are mainly expressed during the 
later blood stages. Furthermore, MSP10 is also subject 
to proteolytic processing similar to MSP1, i.e. in the case 
of MSP10 starting from 30  h post invasion a product 
of 36  kDa can be detected besides the intact protein of 
80 kDa. Puentes et al. aimed at finding out if certain parts 
of MSP10 are capable of binding to erythrocytes and to 
inhibit the invasion of merozoites into new erythrocytes 
[18]. Three MSP10-derived 20-mer peptides showed 
these properties, thus arguing for a role of MSP10 in the 
attachment, re-orientation and/or invasion. Neverthe-
less, human monoclonal antibodies (humAbs) directed 
MSP10 have neither been generated nor characterized 
yet.
The aim of this work was to isolate MSP10-specific 
humAbs from semi-immune donors living in the Ashanti 
region in Ghana, a holoendemic area. Three humAbs, 
humAb10.1, humAb10.2 and humAb10.3, which are spe-
cific for either the first or the second EGF-like domain of 
MSP10, were isolated and characterized in detail.
Methods
Recombinant plasmodial proteins
The recombinant DsRed-fusion proteins featuring EGF-
like domains 1 and 2 of MSP10 as well as EGF-like 
domains from related merozoite surface proteins MSP4 
and MSP8 used in this study were produced transiently 
in Nicotiana benthamiana as previously described [19]. 
Additionally, two multidomain proteins were produced 
in a similar way, both containing the first EGF-like 
domain of MSP119 followed by the above-mentioned set 
of EGF-like domains of merozoite proteins (multi-EGF). 
The second multidomain molecule additionally included 
two blood-stage transcending proteins, Pfs25 from the 
sexual stage and the TSR domain of CSP as a pre-eryth-
rocytic stage component (Figure 1).
Ethics statement and blood donors
Ethical approval for this study was obtained from the 
Committee on Human Research Publication and Ethics 
(CHRPE) of the Kwame Nkrumah University of Science 
and Technology. Written informed consent was obtained 
from all participants after the goals of the study had been 
carefully explained. By the time of donation, the 31 vol-
unteers were between 20 and 45  years old and had not 
had any reported malaria disease for 2 years. From each 
volunteer, 50  ml of heparinized blood was drawn and 
prepared as described below.
Preparation of peripheral blood monocytes (PBMCs) 
from Ghanaian donors
PBMCs were prepared from 50 ml of heparinized periph-
eral blood from each of the 31 donors. The blood was 
diluted in 1 volume of PBS before being layered onto 
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Ficoll (GE Healthcare, Uppsala, Sweden). After centrifu-
gation (800×g, 20  min, 25°C) the PBMCs in the inter-
phase were harvested, washed once in PBS containing 
1% (v/v) FCS (400×g, 10  min, 25°C) and once in PBS 
containing 10% (v/v) FCS (300×g, 10  min, 25°C) before 
being cryopreserved in freezing medium (10% (v/v) 
DMSO in FCS) at cellular concentrations ranging from 
3 to 6  ×  106  cells/ml. The temperature was gradually 
decreased to −80°C (1°C/min) using isopropyl-contain-
ing freezing containers.
ELISA
The reactivity of Ghanaian plasma samples and antibod-
ies in supernatants of lymphoblastoid cell lines (LCLs) 
against MSP10 was assessed by ELISA as described [20]. 
An amount of 100 ng of the respective antigen was coated 
in wells of high-binding ELISA plates overnight at 4°C. 
Wells were washed three times with 0.1% (v/v) Tween20 
in PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 
1.5 mM KH2PO4; pH 7.4) and then blocked with 200 µl 
2% (w/v) milk powder in PBS for 2–3 h at 37°C. Follow-
ing another three washing steps, 50 µl of each superna-
tant or diluted plasma sample was transferred to each 
well. As positive control, a dilution series of a mixture of 
four Ghanaian plasma samples was used. Plasma from 
European malaria-naïve blood donors served as nega-
tive control. Plates were then incubated at 37°C for 1 h. 
After washing three times, goat-anti-human IgG conju-
gated to alkaline phosphatase (AP) (Dianova, Hamburg, 
Germany) in PBS (1:5,000) was added. After an incuba-
tion step at 37°C for 1 h and three washing steps, p-nitro-
phenyl phosphate was added. Absorbance at 405  nm 
was measured after 20–45  min. Based on the reactivity 
of the positive control, a standard curve was fitted with 
Figure 1 Schematic representation of the plant expression cassette and the construct design for the recombinant plasmodial antigens. The gene 
of interest (GOI) is expressed in Nicotiana benthamiana using the vector pTRAc with the shown expression cassette (a). The constructs used during 
this study are summarized including the PlasmoDB number and the amino acid sequences for the respective domains (b). Antigens were either 
expressed as single domain constructs fused to the red fluorescent protein DsRed, or as multi‑domain constructs without DsRed (c). Potential 
N‑glycosylation sites had been removed by replacing relevant asparagine residues by alanine in the first EGF‑like domain of MSP1, the second 
EGF‑like domain of MSP10 and in Pfs25. SAR: scaffold attachment region; CaMV 35S promoter and terminator: promoter with duplicated enhancer 
and terminator of the Cauliflower mosaic virus (CaMV) 35S gene; 5′‑untranslated region: 5′‑UTR of the chalcone synthase gene from Petroselinum 
crispum; signal peptide sequence: transit peptide sequence of the murine antibody 24 heavy chain; GOI Gene of interest.
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a four-parameter logistic model, using the open-source 
software “R” for statistical computing [21].
Fluorescent labelling of antigens
For sorting of antigen-specific B cells, the multidomain 
protein E25T was conjugated to Alexa Fluor® 488 using 
the “Alexa Fluor® 488 5-TFP” kit (Life Technologies, 
Darmstadt, Germany). Labelling efficiency was checked 
according to the manufacturer’s instruction by absorb-
ance measurements at 494 nm (Alexa Fluor® 488 concen-
tration) and 280 nm.
Reduction and alkylation of recombinant plasmodial 
proteins
Recombinantly expressed plasmodial proteins were 
reduced in 5 mM DTT at 56°C for 45 min while shaking. 
The reactions were stopped by adding 15 mM iodoacet-
amide. After incubation for 30  min in the dark, 5  mM 
DTT were added to quench excessive iodoacetamide.
Generation of Epstein‑Barr virus (EBV)‑containing 
supernatants from B95‑8 cells
Marmoset monkey lymphocytes B95-8 (#ACC100, 
DSMZ, Berlin, Germany) were used to generate prepa-
rations of infectious EBV. To this end, cells were seeded 
at a density of 106 cells/ml and kept in RPMI 1640 with 
Glutamax™, 100  U/ml penicillin, 100 μg/ml streptomy-
cin, 10% (v/v) FCS for 4 to 11 days. After centrifugation 
(800×g, 10 min, 25°C) supernatants were passed through 
sterile 0.45 μm-filters, snap frozen in liquid nitrogen and 
stored at −80°C.
Flow cytometric cell sorting
PBMCs from a semi-immune donor were thawed gently, 
washed once in RPMI 1640 containing 10% (v/v) FCS and 
subjected to a staining procedure with a sterile mixture 
of AlexaFluor® 488-labelled antigen (E25T), anti-human 
IgG-RPE (BD Biosciences, Heidelberg, Germany) and 
anti-human CD22-APC (BD Biosciences) in labelling 
buffer (sterile PBS without MgCl2 and CaCl2 containing 
2% (v/v) FCS and 1 mM EDTA, pH 7.4) at 4°C for 30 min 
in the dark. Following three washing steps in ice-cold 
labelling buffer cells were filtered through a 33 µm-mesh, 
taken up in particle-free RPMI 1640 containing 10% (v/v) 
FCS. CD22+/IgG+ antigen-specific mature B cells were 
sorted with a FACSAriaII cell sorter (BD Biosciences) 
and collected in RPMI 1640 containing 20% (v/v) FCS.
EBV transformation of antigen‑specific B cells
B cells selected by cell sorting were then transformed 
as described before with minor modifications [22]. 
B cells were taken up in B cell medium (RPMI 1640 
medium supplemented with l-glutamine, 10 mM HEPES 
buffer, 1 mM sodium pyruvate, 10% (v/v) FCS), 1 µg/ml 
CpG2006 and 30% (v/v) EBV-containing B95-8 super-
natant (3.4  x  108 viral copies/ml). An amount of 50  B 
cells was subsequently seeded onto 100,000 irradiated 
(83 gray) allogeneic PBMCs in 96 well round-bottom tis-
sue culture plates and incubated at 37°C, 5% CO2. After 
2  weeks, supernatants were removed completely and 
replaced by B cell medium containing 1 µg/ml CpG 2006 
and 50  U/ml rhIL-2 (Roche, Basel, Switzerland). After 
another week, supernatants were tested for secretion of 
total and specific IgG.
Dotblot
Dotblots were used to rapidly assess secretion of IgG by 
LCLs and to analyse the nature of MSP10 epitopes. In 
order to check for secreted total human IgG, 3 µl of the 
culture supernatants were transferred onto a nitrocellu-
lose membrane (Roth, Karlsruhe, Germany) and allowed 
to dry for at least 15 min. As positive control, a dilution 
series of a mixture of four Ghanaian plasma samples was 
used ranging from 1:100 to 1:3,200. Blocking was carried 
out in 5% (w/v) non-fat milk powder in PBS for 30 min 
at 25°C. Subsequently, the blocking buffer was substi-
tuted by a 1:5,000 dilution of goat-anti-human IgG-AP in 
5% (w/v) non-fat milk powder in PBS. Following incuba-
tion for 1 h, the membrane was washed thoroughly with 
0.05% (v/v) Triton X-100 in PBS. Detection was carried 
out with NBT/BCIP. To determine whether conforma-
tional or linear epitopes of the antigens are recognized 
by the antibodies, native and reduced/alkylated antigens 
were applied onto nitrocellulose membranes.
Spectratyping
For the characterization of the LCL clonality, genomic 
DNA (gDNA) and RNA were used. The PCR conditions 
and the primers used have been described elsewhere [22]. 
As a monoclonal control gDNA from Ramos cells was 
used; gDNA from PBMCs served as a polyclonal control 
sample. Amplicons were analysed with a 3730 DNA Ana-
lyser (Applied Biosystems/Life Technologies).
Rescue of human immunoglobulin variable regions
RNA and gDNA were prepared either using the “Nucle-
oSpin Tissue” and “NucleoSpin RNA II” kits (Macherey–
Nagel, Düren, Germany) or the “RNeasy Plus Mini” kit 
(Qiagen, Hilden, Germany). Messenger RNA (mRNA) 
from LCLs was reverse transcribed using the “Super-
Script III” kit (Life Technologies). Human heavy chain 
and light chain variable regions (Vh and Vl regions) from 
LCLs were recovered as described before, with minor 
modifications [23]. Our approach differed in that mRNA 
from B cell clusters instead of from single cells was used. 
Moreover, (1) a re-amplification step with the primer set 
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for the first PCRs was included and (2) these sequences 
were cloned into a TopoVector (pCR®II-TOPO®, Life 
Technologies) in order to be able to remove potential 
endogenous cleavage sites. All kits were used according 
to the manufacturers’ instructions.
Bioinformatic analysis of human immunoglobulin variable 
regions
Variable regions were analysed in silico by the IMGT/V-
QUEST algorithm in order to determine the nature of the 
assembled V-, D- and J-gene segments and the germline 
homology [24]. The identity and similarity of the obtained 
Vh and Vl regions compared to their most closely related 
underlying germline sequences was determined by inde-
pendently analyzing each of the underlying gene segments 
by an identity/similarity tool [25]. The respective comple-
mentarity determining regions (CDRs) were identified 
according to the Kabat rules [26]. Alignments were done 
with Clustal Omega [27]. Potential sulfation of tyrosine 
residues was predicted by the Sulfinator algorithm [28].
Cloning
All enzymes for cloning purposes were obtained from 
NEB (Frankfurt am Main, Germany). Amplicons from 
V regions were cloned into pTRAkt plant expression 
vectors. To reconstitute full-size heavy (IgG1) or light 
(Igκ) chain genes, amplicons of the Vh region sequences 
from the second V region-PCR were cloned into a suit-
able pTRAkt vector in frame with a sequence encoding 
a human IgG1 constant domain via AgeI/SalI; Vl-region 
sequences were cloned via AgeI and BsiWI in frame with 
a sequence encoding a human Igκ constant domain as 
previously described [29]. The resulting pTRAkt vectors 
were used for transformation of Agrobacterium tumefa-
ciens (Rhizobium radiobacter) and subsequent transient 
expression of humAbs in Nicotiana benthamiana plants.
Transient expression of recombinant human full‑size IgG 
in Nicotiana benthamiana
Electro-competent agrobacteria (Agrobacterium tumefa-
ciens strain GV3101: pMP90RK with resistance to gen-
tamycin, kanamycin and rifampicin) were transformed 
with one of the following pTRA vectors: pTRAc-p19si, 
pTRAkt_H_5E8, pTRAkt_H_5F6, pTRAkt_κ_5E8, or 
pTRAkt_κ_5F6 as previously described [19, 30]. Plants 
were 8–10 weeks old by the time of infiltration and had 
been raised in rock wool in a phytotron as described pre-
viously [30]. Plants were immersed into the agrobacte-
rial suspension, infiltrated for 1  min at 5  kPa, 25°C and 
then cultivated for 5  days with steady light and regular 
watering, i.e. spraying for 1 min every 3 h. After 5 days of 
incubation the infiltrated plants were harvested. Leaves 
were shredded in two to three volumes of extraction 
buffer (PBS containing 10 mM Na2SO5; pH 7.4, 4°C) for 
1 min. Insoluble material and plant fibers were removed 
by filtration through Miracloth. Then, 500 mM NaCl was 
added, pH was adjusted to 8.2 and the suspension was 
incubated at 4°C for 1 h. Precipitated material was then 
removed by centrifugation (17,000×g, 30 min, 4°C) and a 
successive filtration step using 0.45 µm-filters.
Antibody purification by Protein A chromatography
HumAbs were purified from Nicotiana benthamiana 
extracts as well as lymphoblastoid cell culture superna-
tants by Protein A chromatography using MabSelect™ 
SuRe™ Sepharose (GE Healthcare). The purification 
matrix was equilibrated with binding/washing buffer 
(0.2  M Tris–HCl, pH 9.0) prior to the affinity chroma-
tography. Antibodies were eluted with 0.2  M Sodium 
Citrate, pH 2.5, elution fractions were neutralized by 1 M 
Tris, pH 9.0 and dialyzed against PBS. For use in in vitro 
growth inhibition assays (GIAs) antibodies were concen-
trated in RPMI 1640 incl. 25 mM HEPES (PAA, E15-041), 
using Vivaspin 15R 30,000 MWCO centrifugal concen-
trators (VWR 512-4124) and sterilized by filtration.
Plasmodium falciparum culture
Plasmodium falciparum strain 3D7A was cultured as 
described before [31]. Briefly, parasites were maintained 
at a haematocrit of 5% (v/v) in parasite culture medium 
[RPMI 1640, 25 mM HEPES, 2 mM l-glutamine, 50 μg/
ml gentamycin, 10% (w/v) Albumax®II (Life Technolo-
gies)]. Erythrocytes of 12–16 individual donors, all hav-
ing the blood group 0, Rh-positive, were obtained in 
CPDA tubes from the Department for Transfusion Medi-
cine, RWTH Aachen University Clinic, Aachen, Ger-
many. The suspensions were mixed, centrifuged in order 
to remove plasma and white blood cells (650×g, 5  min, 
25°C, without break) and washed for three times in SAG-
mannitol (150  mM NaCl, 50  mM d-glucose, 1.2  mM 
adenine, 28.8 mM D(-)-mannitol). Washed erythrocytes 
were taken up in SAG-mannitol to obtain a final haema-
tocrit of 66.6% (v/v).
In vitro growth inhibition assay (GIA)
In vitro growth inhibition of the isolated antibodies was 
assessed via GIA on P. falciparum as described before 
using humAbs in final concentrations ranging from 10 
to 0.078 mg/ml in RPMI 1640 containing 25 mM HEPES 
[32]. As positive control, 6 mg/ml polyclonal rabbit-anti-
AMA1 IgG (BG98) was used [33]. As corresponding 
negative control 6 mg/ml polyclonal IgG of a naïve rab-
bit were used. The humAb 2G12, an HIV-1-specific IgG, 
was taken as a plant-expressed non-specific control [34]. 
P. falciparum 3D7A were synchronized by three sorbitol 
treatments 7, 5 and 3 days prior to the GIA [35]. Schizont 
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stage parasites were seeded at 0.3 or 0.4% parasitaemia 
in 2% (v/v) haematocrit. Each GIA was performed with 
50  μl final volume in 96-well flat-bottom half-area cul-
ture plates. After an incubation period of 44 h, GIAs were 
harvested and frozen at -20°C for at least 16 h. Parasite 
growth was estimated by a pLDH-assay [36]. The per-
centage of relative growth inhibition was calculated as 
follows: % inhibition = 100 × [A655 nm (sample) − A655 nm 
(erythrocyte control)]/[A655 nm (schizont growth control) 
− A655 nm (erythrocyte control)].
Immunofluorescence assay
Synchronous P. falciparum 3D7A were used to prepare 
IFA slides. Smeared parasites were fixed in methanol at 
−20°C for 10 min. After blocking in 1% (v/v) FCS (low IgG) 
in PBS for 3 h at 25°C, slides were incubated with 50 µg/
ml mouse-anti-MSP4 and either of the three human-anti-
MSP10 antibodies (10 or 25  µg/ml) or 2G12 (an anti-gp 
120 HIV-1 humAb as isotype control for human IgG) in 
1% (v/v) FCS (low IgG), 0.01% (w/v) Saponin in PBS) in 
a moist box at 25°C for 1  h. After four washing steps in 
PBS, the slides were treated with 1:100 goat-anti-mouse 
IgG(H + L)-Alexa Fluor® 488 (Life Technologies), 1:1,000 
goat-anti-human IgG(H  +  L)-Cy3 (Dianova) and 10  µg/
ml Hoechst 33342 (Life Technologies) in a moist box at 
25°C for 1 h. Five washing steps were carried out. Prolong® 
Antifade mounting medium (Life technologies) was used 
to conserve the staining. Images were taken at a 630× 
magnification with a Leica TCS SP8 microscope and LAS 
AF Version 3.1.3 software (Leica, Solms, Germany).
Surface plasmon resonance (SPR) spectroscopy
Kinetic binding parameters of the monoclonal antibod-
ies were analysed by SPR spectroscopy using a Biacore 
T200 instrument (Biacore, GE Healthcare, Uppsala, Swe-
den) and Protein A-functionalized CM5-S series sensor 
chips as previously described [29]. For kinetic analysis, 
100–180 RU of the different humAbs were captured onto 
immobilized protein A and recombinant multi-EGF (0.1–
540 nM) was injected at a flow rate of 30 µl/min for 180 s. 
Dissociation was tracked for 600  s. Between measure-
ments, the surface was regenerated by pulsing for 1 min 
with 30 mM HCl. Buffer injections were used for double 
referencing. All measurements were performed at 25°C 
using HBS-EP (10  mM Hepes, 150  mM NaCl, 3.4  mM 
EDTA, 0.005% (v/v) Tween-20) as running buffer. Binding 
curves were evaluated using BIAEval 4.0 (GE Healthcare).
Results
Reactivity of plasma from Ghanaian semi‑immune donors 
against MSP10 EGF‑like domains
The study was designed to efficiently isolate humAbs 
which recognize the EGF-like domains of MSP10 and 
which represent a part of the naturally-acquired, protec-
tive immunoglobulin repertoire of semi-immune donors. 
The definition of semi-immunity of the plasma donors 
was primarily based on observation that they had not 
shown any signs of clinical malaria for 2  years. Moreo-
ver, several screenings had been performed to make sure 
that the set of donors had a broad anti-malarial antibody 
response, as published before [13, 19, 30, 37–39].
To quantify the MSP10-response, plasma of 31 
Ghanaian blood donors were screened for reactivity 
against DsRed-MSP10(EGF1) (Figure  2a) and DsRed-
MSP10(EGF2) (Figure  2b). In order to exclude back-
ground binding of the plasma samples against the fusion 
partner DsRed, background reactivity against DsRed 
was measured as well and subtracted from the reactivity 
against the respective fusion protein (Figure 3a). In this 
ELISA, 15 plasma samples (48%) showed specific reactiv-
ity (>reactivity of negative control + 2 × standard devia-
tions) against DsRed-MSP10(EGF1); 15 (48%) showed 
specific reactivity against DsRed-MSP10(EGF2). Interest-
ingly, eleven of these recognized both EGF-like domains 
of MSP10. Therefore, B cells from these individuals 
appeared to be a suitable source of pan-MSP10 EGF-like 
domain humAbs.
It had been reported that naturally acquired antibod-
ies which are specific for plasmodial EGF-like domains 
primarily react with conformational epitopes [17, 40, 41]. 
Thus, these data were especially confirmed for MSP10. To 
this end, native as well as reduced and alkylated form of 
the multi-EGF fusion protein, containing both EGF-like 
domains of MSP10, was used for an ELISA with 13 of the 
Ghanaian plasma samples which were positive for either 
or both EGF-like domains of MSP10 (Figure  3b). The 
reactivity of each of the semi-immune plasma samples 
was reduced to background level when the antigen had 
been reduced and/or alkylated demonstrating that IgG of 
the semi-immune donors specifically recognize confor-
mational epitopes of the MSP10 EGF-like domains.
Figure 2 Epidermal growth factor (EGF)‑like domains of MSP10. The 
sequences of the EGF‑like domains one (a) and two (b) of MSP10 
from the Plasmodium falciparum parasite strain 3D7A are shown. Con‑
necting lines between the cysteine residues represent the disulfide 
bridges. Sequences were derived from http://www.uniprot.org/uni‑
prot, accession number C6HT44. An asparagine residue was replaced 
by an alanine (N462A, boxed) in order to prevent N‑glycosylation in 
plants.
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Selection and EBV transformation of mature IgG+ 
antigen‑specific B cells
For selection of mature, IgG+, merozoite surface antigen-
specific B cells as basis for the subsequent EBV trans-
formation, PBMCs from donor G13, one of the donors 
whose plasma reacted with both of the MSP10 EGF-
like domains, were used. An amount of 1.25 × 107 vital 
PBMCs was subjected to flow cytometric sorting and 
4,869 vital CD22+/IgG+ B cells (0.039%) were selected 
and seeded for EBV transformation. After 7  weeks, 6 
out of 90 wells (6.67%) showed reactivity with the multi-
domain fusion protein E25T, which includes both EGF-
like domains of MSP10. The corresponding LCLs were 
expanded. Fifteen weeks after EBV transformation four 
of these six cultures had ceased to secrete specific IgG. 
The remaining two cultures, 5E8 and 5F6, were used for 
clonal analyses by spectratyping and rescue of Vh and Vl 
sequences by PCR.
Spectratyping revealed that LCL 5F6 was monoclonal 
as early as 16  weeks post infection. At that time point 
LCL 5E8 was still octaclonal. After continuous subcultur-
ing of the LCL 5E8 for another 21 weeks, it also became 
monoclonal.
Rescue and analysis of antibody variable sequences
Each of the LCLs 5E8 and 5F6 were subjected to RNA 
isolation, cDNA synthesis and amplification of immu-
noglobulin Vh-, Vk- and Vl- region sequences. From 
each culture, one Vh and one Vk were recovered. Subse-
quently, the Vh and Vl regions were sequenced and com-
pared to the closest corresponding germline sequences. 
As shown in Figure  4, 60 DNA mutations in the Vh 
5E8 sequence and >40 DNA mutations in the Vl 5E8 
sequence led to 31 and 16 amino acid changes, respec-
tively (Figure  4a, b). Sequence alignments for Vh 5F6 
(Figure  4c) and Vl 5F6 (Figure  4d) revealed 21 changes 
(≥45 DNA mutations) and 12 changes (≥26 DNA muta-
tions), respectively.
Recombinant expression of humAbs
Variable region sequences of 5E8 and 5F6 were cloned 
into pTRAkt vectors for recombinant transient expres-
sion in Nicotiana benthamiana. Since antibody heavy 
and light chains are encoded on separate pTRAkt plant 
expression plasmids it is possible to realize any HC/LC 
combination. After initial small scale expression stud-
ies three (H5F6:κ5E8, H5F6:κ5F6 and H5E8:κ5E8) of the 
four possible Vh/Vl combinations recognized MSP10. 
Subsequently, the three corresponding binding-com-
petent humAbs were transiently expressed at a medium 
scale (10-16 Nicotiana benthamiana plants). Heavy 
chain 5F6 (H5F6) was either co-expressed with the light 
chain 5E8 (κ5E8) or 5F6 (κ5F6), respectively, resulting in 
humAb10.1 (H5F6:κ5E8) and humAb10.2 (H5F6:κ5F6). 
Heavy chain 5E8 (H5E8) was co-expressed with its 
natural light chain (κ5E8), thus forming humAb10.3 
(H5E8:κ5E8). The average yield of the recombinant anti-
bodies was 100-200 mg per kg of fresh leaf material.
Specific binding comparison between antibodies from LCL 
supernatants and respective recombinant humAbs
The reactivity of the humAbs against MSP10(EGF1) 
and MSP10(EGF2) was verified by ELISA with DsRed-
MSP10(EGF1), DsRed-MSP10(EGF2) and multi-EGF 
Figure 3 Reactivity of Ghanaian plasma samples against both EGF‑like domains of MSP10. a Reactivity of 31 Ghanaian plasma samples and a 
European non‑immune control plasma pool (NIP) were tested against the first (red bars) or second (green bars) EGF‑like domain of MSP10 by ELISA. 
Reactivities were measured against the DsRed‑MSP10(EGF) fusion protein. Thus, the background reactivity against DsRed, which was very low in 
all samples (absorbance at 405 nm below 0.1), was subtracted from all samples. Values represent relative reactivities in comparison to the positive 
control pool, whose reactivity was set to “1”. b Plasma samples positively reacting to MSP10 were also tested for reactivity against the reduced and 
alkylated antigen multi‑EGF. All data were measured in technical triplicates. Error bars represent the standard deviation of sample results.
Page 8 of 16Maskus et al. Malar J  (2015) 14:276 
comprising both EGF-like domains of MSP10. All 
humAbs bound to multi-EGF (Figure  5). The recombi-
nant humAb10.3 and the homologous LCL 5E8 super-
natants similarly reacted with MSP10(EGF2), but not 
MSP10(EGF1). Likewise and complementarily, LCL-
derived IgG 5F6 and recombinant humAb10.2 recog-
nized MSP10(EGF1), but not MSP10(EGF2). The shuffled 
antibody humAb10.1, which by definition could only be 
recombinantly expressed, recognized the first EGF-like 
domain of MSP10 and thus showed the same specificity 
as humAb10.2.
The affinity of the humAbs to MSP10 was ana-
lysed by SPR spectroscopy using the multi-EGF fusion 
protein, which is monovalent and contains several EGF-
like domains of the MSP family including both EGF-like 
domains of MSP10. Kinetic constants ka, kd and KD of both 
humAb10.2 and humAb10.3, produced in different expres-
sion systems, were determined. The KD values of all anti-
bodies are summarized in Table 1. High association rates 
(ka) for both humAb10.2 and humAb10.3 were observed. 
However, the dissociation rate (kd) of humAb10.3 
was lower than the one of humAb10.2, indicating that 
humAb10.3 possesses a higher affinity for MSP10(EGF2) 
than humAb10.2 for MSP10(EGF1). The affinity of the 
humAb10.1, which is composed of the artificial combina-
tion of H5F6:κ5E8, to its antigen MSP10(EGF1) was more 
Figure 4 Alignment of Vh and Vl sequences of 5E8 and 5F6 with their respective germline sequence. The amino acid sequences of the obtained 
human antibody V region sequences rescued from LCLs 5E8 (a, b) and 5F6 (c, d) were aligned to their respective germline sequence, as obtained by 
the IMGT/V‑Quest Tool [24]. Joining region elements containing N‑nucleotides between the V‑, D and J‑segments for the Vh (a, c) are marked by the 
undefined amino acid X. CDR1‑3 (boxes) are labelled according to the Kabat definition.
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than 100-fold lower than the affinity of humAb10.2 for the 
same antigen. The recombinant humAb10.2 and the cor-
responding LCL-derived 5F6 antibody showed a compara-
ble affinity to the antigen MSP10(EGF1). Surprisingly, the 
affinity of the humAb10.3 expressed in plants differs by a 
factor of seven from the respective antibody produced by 
the corresponding LCL (5E8).
A potential explanation for this difference might be a 
posttranslational modification of the antibody, e.g. the 
sulfation of tyrosine residues, which is assumed not to 
take place in plants [42]. Therefore, in silico analysis was 
performed using the Sulfinator tool [28]. Two residues 
in the CDR1 (LRSMSDYY) and one residue in the CDR3 
(DSAVYYCQQYED) of the heavy chain of humAb10.3 
were predicted to be sulfated in mammalian expression 
systems.
Recognition of conformational epitopes of humAb10.1, 
humAb10.2 and humAb10.3
Knowing that antibodies of the protective immuno-
globulin repertoire of semi-immune individuals mainly 
recognize correctly folded plasmodial EGF-like domains 
as shown in Figure  3b and by others [17, 40, 41], anti-
bodies humAb10.1, humAb10.2 and humAb10.3 were 
tested for their binding capacities against conformational 
epitopes of different members of the merozoite surface 
protein family and MSP10. Analysis by dotblots showed 
that all three humAbs bound conformational epitopes of 
MSP10(EGF1) or MSP10(EGF2), respectively, but did not 
bind to their reduced counterparts. Moreover, they did 
not cross-react with other plasmodial EGF-like domains 
of MSP1, MSP4 or MSP8.
In conclusion, all human antibodies described here 
only bind the native antigen, thus recognizing a confor-
mational epitope. Secondly, all three antibodies bind 
highly specific to MSP10 EGF-like domains, and do not 
show any cross-reactivity (Figure 6).
Figure 5 Specific reactivity of antibodies produced by the LCLs versus their derived recombinant humAbs. Using ELISA, the specific reactivity of 
the antibodies from the supernatant of LCLs (undiluted, three‑day culture) as well as the derived recombinant humAbs transiently produced in 
Nicotiana benthamiana against the first (red bars) or second (green bars) EGF‑like domain of MSP10 and multi‑EGF containing a series of plasmo‑
dial EGF‑like domains (blue bars). Represented values reflect the reactivity against the fusion proteins corrected by the reactivity observed with 
the his‑tagged control protein (DsRed). Recombinantly expressed and purified humAb10.1 (H5F6:κ5E8), humAb10.2 (H5F6:κ5F6) and humAb10.3 
(H5E8:κ5E8) were applied in concentrations of 150, 1.5 and 3 µg/ml, respectively. A pool of Ghanaian plasma samples at a dilution of 1:200 served 
as positive control, a pool of naïve plasma samples as negative control. Plain B cell medium was used as negative control for the LCL. The ELISA was 
performed in technical triplicates; the error bars represent the standard deviations.
Table 1 Affinities (KD values) of  purified humAb10.1, 
humAb10.2 and  humAb10.3 as  determined by  SPR spec-


















5.31 × 105 2.90 × 10−3 5.46 × 10−9






2.32 × 105 1.15 × 10−3 5.39 × 10−9
LCL 5E8 3.99 × 105 3.06 × 10−4 8.04 × 10−10
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IFA of the anti‑MSP10 humAbs
In order to validate, if the antibodies not only recog-
nize recombinantly produced EGF-like domains of 
MSP10, but also naturally expressed MSP10, we per-
formed immunofluorescence assays. To this end, seg-
mented P. falciparum 3D7A schizonts were used for 
confocal microscopy with humAb10.1, humAb10.2 and 
humAb10.3 (Figure 7). As counterstain, a murine mono-
clonal MSP4(EGF)-specific antibody was used [29]. As 
an isotype control of human IgG, the anti-gp 120 HIV-1 
humAb 2G12 instead of the MSP10-specific humAb was 
used. No signal was detected in this setup. HumAb10.1 
(Figure  7a), humAb10.2 (Figure  7b) and humAb10.3 
(Figure 7c) showed partial co-localization with the anti-
MSP4 antibody. Additionally, the humAbs recognized a 
dot-like structure at the apical end of the preformed mer-
ozoites in the schizont stage.
Inhibition of P. falciparum 3D7A growth by MSP10‑specific 
humAbs in vitro
In order to test the inhibitory potential of humAb10.1, 
humAb10.2 and humAb10.3, an in vitro-GIA with P. fal-
ciparum strain 3D7A was performed. All three antibodies 
showed a concentration-dependent inhibition of P. falci-
parum 3D7A (Figure 8). However, an inhibition of 100% 
was not reached by any of the antibodies at the applied 
Figure 6 Dotblots with native and reduced EGF‑like domains of P. falciparum merozoite surface proteins. Native proteins MSP119, DsRed‑fusion 
proteins of MSP8(EGF1), MSP8(EGF2), MSP4(EGF), MSP10(EGF1) and MSP10(EGF2), multi‑EGF and DsRed were applied in the indicated amounts. 
Proteins containing any of the EGF‑like domains of MSP10 were also reduced and alkylated and used in the same quantity. The Ghanaian plasma 
pool (a) and the naïve plasma pool (b) were used in a 1:500 dilution. Recombinantly expressed and purified humAb10.1 (c), humAb10.2 (d) and 
humAb10.3 (e) were used in concentrations of 100, 50 and 1.4 µg/ml, respectively. As secondary antibody, goat‑anti‑human IgG‑AP (Dianova) at a 
dilution of 1:5,000 was used.
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concentrations; the maximum inhibition of all antibod-
ies ranged between 60 and 70%. HumAb10.1 inhibited P. 
falciparum 3D7A most efficiently with an EC50 value of 
4.1 mg/ml (95% confidence interval (CI) 2.6–6.6 mg/ml), 
humAb10.2 inhibited the parasite growth with an EC50 
value of 6.9  mg/ml (CI 5.5–8.6  mg/ml) and humAb10.3 
inhibited the merozoite invasion with at an EC50 value of 
9.5 mg/ml (CI 5.5–16.4 mg/ml).
Discussion
So far, only a handful of anti-plasmodial humAbs have 
been isolated and described. Some of these are specific 
for the MSPs (MSP1, MSP2 and MSP3) or GLURP [43–
46]. Others show specificity for the plasmodial proteins 
expressed on the erythrocyte surface, such as VAR2CSA, 
RESA and the Plasmodium vivax DBP [47–49]. Another 
work also describes humAbs specific for the sexual 
stage of the parasite (Pfs48/45) or the sporozoite stage 
((NPNA)3-repeat of CSP) [50, 51].
Here, additional human antibodies specific for the 
merozoite surface, isolated by an innovative human 
antibody technology platform, are presented. This tech-
nology combines the screening of naturally exposed 
semi-immune individuals from endemic countries for 
antigen-specific reactivity, the targeted selection of anti-
gen-specific B cells by flow cytometric sorting, the sub-
sequent EBV transformation, rescue of the antibody V 
region sequences and subsequent recombinant produc-
tion in plants. This allows to produce different versions 
of the antibody, the antibodies produced directly in the 
Figure 7 IFAs of recombinantly expressed humAbs P. falciparum 3D7A schizonts. Binding of humAb10.1, humAb10.2 and humAb10.3 to schizonts 
was assessed by IFA. Parasites were co‑stained with a mouse‑anti‑MSP4 antibody (green), Hoechst 33342 nuclear stain (blue) and either of the three 
recombinant humAb10.1 (a), humAb10.2 (b) and humAb10.3 (c) (red). Human and murine antibodies were detected by fluorescently labelled anti‑
bodies goat‑anti‑human IgG (H + L)‑Cy3 (Dianova) and goat‑anti‑mouse IgG (H + L)‑Alexa Fluor® 488 (Life Technologies), respectively. Images were 
taken at a 630× magnification with a Leica TCS SP8 microscope. The right panel shows the overlay of the three fluorescence images. Scale bar 5 µm
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LCLs, as well as the recombinant antibody. Combinations 
of different heavy and light chains can only be produced 
using recombinant antibodies. Moreover, the slight dif-
ference in affinity of humAb10.3, which likely relies on 
posttranslational modifications, can only be detected 
when comparing multiple expression systems.
The rescue of the antibody variable sequences is espe-
cially important, as LCLs tend to cease to secrete anti-
bodies or stop to proliferate altogether, which would 
lead to an irreversible loss of the desired immunoglobu-
lin [52]. In contrast, the transient antibody production 
in plants allows for rapid and scalable production, rang-
ing from the infiltration of individual leaves to multi-
ple plants by vacuum infiltration [29, 34]. The humAbs 
described here were produced in this transient produc-
tion system and showed a yield of more than 100 mg per 
kg of plant material. This is in the range of very well pro-
ducing antibodies which have previously been described 
[53, 54].
The first step of the procedure, the screening of plasma 
for specific antigen-binding, provides valuable informa-
tion: On the one hand, the positive reactivity shows that 
specific antibodies are present in the subjects tested; on 
the other hand, it validates that the recombinant antigens 
produced in Nicotiana benthamiana are correctly folded. 
The general reactivity of these plasma samples against 
various P. falciparum antigens has previously been shown 
elsewhere [19, 29, 30, 37–39]. Regarding the EGF-like 
domains of MSP10 described here, in total approx. two-
thirds of the tested plasma samples reacted with at least 
one of the two domains. In the case of the other plasmo-
dial EGF-like domains it is also known that these are not 
recognized by all sera of semi-immune individuals; e.g. 
the double EGF-like domain of MSP119 [55]. Moreover, 
the observation that Ghanaian plasma samples primar-
ily reacted with discontinuous epitopes of the EGF-like 
domains of MSP10 is in line with findings of the first 
description of the antigen MSP10 [17]. Coherent thereto, 
the isolated antibodies humAb10.1, humAb10.2 and 
humAb10.3 just bind to the native antigen and do not 
recognize reduced MSP10.
It was found that each of the isolated antibody chains 
had accumulated a considerable number of coding muta-
tions during their affinity maturation in  vivo. It can be 
assumed that it takes 4 years to accumulate 20 mutations 
in the Vl and 30 mutations in the Vh sequences for a 
desirable affinity maturation to occur [56]. Consequently, 
it is likely that the in  vivo-maturation of humAb10.2 
(H5F6:κ5F6) and humAb10.3 (H5E8:κ5E8) took at least 
2–3 years and 3–4 years, respectively. This is well in line 
with the observation that it takes years for a protective 
anti-plasmodial immunoglobulin repertoire to arise 
[6–8].
By ELISA and SPR spectroscopic measurements it 
was demonstrated that (1) the correct variable regions 
of LCLs 5E8 and 5F6 were rescued and that (2) the 
corresponding recombinant IgG1:κ full-size antibod-
ies shared the same characteristics with their natu-
rally produced counterparts. It appears that the correct 
variable sequences had been recovered, cloned and 
expressed in the context of IgG1:κ given the facts that 
(1) LCLs 5E8 and 5F6 were monoclonal by the time of 
the rescue of their variable immunoglobulin regions 
and that (2) naturally and recombinantly produced 
humAb10.2 and humAb10.3 showed the same respec-
tive specificities. Interestingly, the artificial combination 
H5F6:κ5E8 of humAb10.1 featured the same specificity 
for MSP10(EGF1) as humAb10.2 (H5F6:κ5F6). However, 
humAb10.1 was much less affine for MSP10(EGF1) than 
humAb10.2 (Table 1). This can likely be explained by the 
facts that the CDRs of both Vh and Vl regions of each B 
cell receptor are simultaneously selected for in vivo and 
that all six CDRs contribute to complementarity, specific-
ity and affinity to the epitope. Thus, the features of a par-
atope formed by an artificial Vh:Vl combination are likely 
to be compromised and may result in loss of affinity or 
even specificity. The fact that humAb10.1 still recognized 
Figure 8 In vitro GIA of P. falciparum 3D7A. Plasmodium falciparum 
3D7A had been synchronized three times prior to the start of the 
GIA at schizont stage. Recombinant humAb10.1 (black triangles), 
humAb10.2 (green circles) and humAb10.3 (red squares) have been 
purified by Protein A chromatography, concentrated, re‑buffered in 
culture medium, sterilized by filtration and were applied in final con‑
centrations of up to 10 mg/ml. The plates were harvested after 44 h 
and the growth of parasites estimated by a pLDH assay. All tests were 
carried out in technical triplicates; error bars correspond to standard 
deviation values.
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MSP10(EGF1) argues for a major role of the heavy chain 
CDRs in the recognition of MSP10(EGF1). This is in line 
with the finding that in many antibodies CDRH2 and 
CDRH3 contribute most to the free binding energy [57].
IFAs using humAb10.1, humAb10.2 and humAb10.3 
showed a fluorescence pattern which closely resembles 
the one seen before by Black et  al. [17]. The antibodies 
bound to the merozoite surface and marked a specific 
spot in the region of the apical end of the merozoite. 
This is consistent with a localization at the rhoptries, the 
micronemes or a predominant localization at the apical 
end of the merozoite.
The EGF-like domains of MSP10 are very conserved 
[17, 58, 59], which argues for a critical role that does 
not allow for many changes in amino acid sequence and 
structure. It is tempting to believe that such invariable 
epitopes on free merozoites exposed to the serum con-
stitute an Achilles’ tendon for inhibitory antibodies. Nev-
ertheless, the inhibitory concentrations of the presented 
humAbs are relatively high. As compared to other anti-
plasmodial antibodies, such as AMA1- or Rh5-reactive 
IgG showing EC50 values of as low as 50–240 µg/ml [60, 
61], the inhibition of P. falciparum by either MSP10-spe-
cific humAb thus appears relatively inefficient. To get a 
more precise idea of the general inhibitory potential of 
naturally-acquired antibodies against MSP10, it would 
be highly informative to purify antibodies against MSP10 
by affinity purification and subsequently measure their 
inhibitory potential. Unfortunately, we were not able to 
perform such an experiment due to the limited availabil-
ity of the respective plasma samples.
Puentes et al. found three synthetic 20-mer peptides 
of MSP10 to be binding to human erythrocytes and to 
be hampering the invasion of merozoites into eryth-
rocytes in  vitro. Interestingly, one of these peptides 
corresponds to a part of the first EGF-like domain of 
MSP10 and showed 65% (±2%) inhibition at a concen-
tration of 200 µM (0.46 mg/ml) [18]. The EC50 values 
of the antibodies described in the present work range 
from 4.1 to 9.5  mg/ml. This corresponds to a molar 
concentration range between 27 and 63 µM. Thus, the 
EC50 values of the presented humAbs are well below 
the concentrations needed for the linear peptides of 
MSP10, but still way above the the EC50 values of some 
antibodies against AMA1 and or Rh5, as described 
above. The probable mechanism of the MSP10-specific 
humAbs is the direct blocking of the binding of the 
merozoite to the erythrocyte, and thereby inhibiting 
the attachment/invasion. In case of MSP1, antibodies 
directed at MSP119, the portion which is comparable 
to the EGF-like domains of MSP10, can be classified 
as inhibitory, neutral or blocking (i.e. counteract-
ing the inhibition by other MSP1-specific antibodies) 
depending on their activity [62]. Given the similarity 
of the C-terminal parts of MSP1 and MSP10, the ques-
tion remains which category applies to humAb10.1, 
humAb10.2. and humAb10.3. As this is the first 
description of monoclonal antibodies against the anti-
gen MSP10, we cannot make this classification yet for 
the antibodies described here. The dissection of the 
actual mechanism would be a valuable subject of fur-
ther investigations.
However, besides mere binding to the target, antibod-
ies may also fulfil their function in vivo by initiating the 
complement cascade [63] and/or by recruiting immune 
effector cells. GIAs, such as the one used in this study, 
only address direct neutralization capacity. Therefore, it 
would make sense to perform tests which incorporate 
monocytes or neutrophil granulocytes [13, 64]. Addition-
ally, it may be possible that the monoclonal antibodies 
characterized herein cannot completely inhibit the para-
site invasion on their own. Rather, they could contribute 
to a synergistic neutralization when combined with anti-
bodies of different anti-malarial specificities.
Besides a function during attachment to/invasion of 
new erythrocytes, the EGF-like domains of MSP10 might 
be carried into the erythrocyte during invasion and 
might have a function during the development of mero-
zoites into rings. EGF-like domains of MSP1, MSP2 and 
MSP4 have been reported to stay attached to the merozo-
ite membrane by GPI anchors after processing and to be 
carried into the freshly infected erythrocyte [11, 65, 66]. 
It has been assumed that some MSP119-specific antibod-
ies may compromise the intraerythrocytic development 
of Plasmodia [67, 68]. Thus, further studies may address 
the question if the C-terminal portion of MSP10, which 
comprises the EGF-like domains, also remains bound 
to the merozoite until after invasion. This might pave 
the way for the evaluation of MSP10 as a target of anti-
malarial fusion proteins [69].
Conclusion
The presented work describes the generation and 
characterization of three humAbs which are specific 
for the first or the second EGF-like domain of MSP10, 
respectively. To the best of our knowledge this study 
is the first to combine flow cytometric selection of 
antigen-specific B cells with EBV transformation and 
to successfully generate humAbs by this very tech-
nique. To our knowledge, these are the first human 
monoclonal antibodies directed at MSP10, which 
have been isolated. HumAb10.2 and humAb10.3 pos-
sess the genuine combination of corresponding heavy 
and light chains, respectively; they are highly specific 
for their corresponding plasmodial EGF-like domain 
and bind these with high affinity. In in vitro GIAs, the 
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MSP10-specific humAbs demonstrated significant 
inhibition of the parasite strain 3D7A even though 
comparatively high antibody concentrations were 
required. Further experiments should address (1), the 
potential role of immune effector cells in inhibition 
of merozoites by MSP10-specific antibodies and (2), 
the identification of interaction partners of MSP10 to 
deepen understanding of its function(s). The gener-
ated humAbs represent a valuable tool to tackle these 
MSP10 related questions in the future.
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